{"id":"https://openalex.org/W4361256752","doi":"https://doi.org/10.1158/0008-5472.22417124.v1","title":"Supplemental Figures 9-12 from Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer","display_name":"Supplemental Figures 9-12 from Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361256752","doi":"https://doi.org/10.1158/0008-5472.22417124.v1"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.22417124.v1","doi":"https://doi.org/10.1158/0008-5472.22417124.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22417124.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/0008-5472.22417124.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061034435","display_name":"Jason P.W. Carey","orcid":"https://orcid.org/0000-0002-9729-1742","observed_orcids":["https://orcid.org/0000-0002-9729-1742"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jason. P.W. Carey","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011734599","display_name":"Cansu Karaka\u015f","orcid":"https://orcid.org/0000-0003-0357-5224","observed_orcids":["https://orcid.org/0000-0003-0357-5224"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cansu Karakas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000113218","display_name":"Tuyen N. Bui","orcid":"https://orcid.org/0000-0001-8509-3653","observed_orcids":["https://orcid.org/0000-0001-8509-3653"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tuyen Bui","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100422537","display_name":"Xian Chen","orcid":"https://orcid.org/0009-0000-5344-6012","observed_orcids":["https://orcid.org/0009-0000-5344-6012"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xian Chen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006097717","display_name":"Smruthi Vijayaraghavan","orcid":"https://orcid.org/0000-0002-8131-0988","observed_orcids":["https://orcid.org/0000-0002-8131-0988"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Smruthi Vijayaraghavan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100362747","display_name":"Yang Zhao","orcid":"https://orcid.org/0000-0003-0200-7575","observed_orcids":["https://orcid.org/0000-0003-0200-7575","https://orcid.org/0009-0000-4400-8934"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yang Zhao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100378341","display_name":"Jing Wang","orcid":"https://orcid.org/0000-0002-5398-0802","observed_orcids":["https://orcid.org/0000-0002-5398-0802","https://orcid.org/0009-0006-4171-5397","https://orcid.org/0000-0002-8911-9555","https://orcid.org/0009-0003-0661-5954"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jing Wang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058106142","display_name":"Keith W. Mikule","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Keith Mikule","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014713051","display_name":"Jennifer Keating Litton","orcid":"https://orcid.org/0000-0001-8390-4985","observed_orcids":["https://orcid.org/0000-0001-8390-4985"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer K. Litton","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017411324","display_name":"Kelly K. Hunt","orcid":"https://orcid.org/0000-0001-9156-8723","observed_orcids":["https://orcid.org/0000-0001-9156-8723"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kelly K. Hunt","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5042960706","display_name":"Khandan Keyomarsi","orcid":"https://orcid.org/0000-0002-5440-0849","observed_orcids":["https://orcid.org/0000-0002-5440-0849"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Khandan Keyomarsi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/synthetic-lethality","display_name":"synthetic lethality","score":0.9679999947547913},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.9950000047683716},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.9860000014305115},{"id":"https://openalex.org/keywords/niraparib","display_name":"niraparib","score":0.8989999890327454},{"id":"https://openalex.org/keywords/dinaciclib","display_name":"dinaciclib","score":0.8759999871253967},{"id":"https://openalex.org/keywords/10058-f4","display_name":"10058-F4","score":0.9599999785423279},{"id":"https://openalex.org/keywords/brca-status","display_name":"BRCA mutation status","score":0.7580000162124634},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.6859999895095825}],"concepts":[{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.8197444677352905},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.605285108089447},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.5728074908256531},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5491325259208679},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5107000470161438},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.480866014957428},{"id":"https://openalex.org/C2778502085","wikidata":"https://www.wikidata.org/wiki/Q7662767","display_name":"Synthetic lethality","level":4,"score":0.45606908202171326},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.4481314420700073},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3806415796279907},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.37700384855270386},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33347228169441223},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.24639201164245605},{"id":"https://openalex.org/C134935766","wikidata":"https://www.wikidata.org/wiki/Q210538","display_name":"DNA repair","level":3,"score":0.11768442392349243},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.0851362943649292},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.07396528124809265},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.07302603125572205},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/0008-5472.22417124.v1","doi":"https://doi.org/10.1158/0008-5472.22417124.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22417124.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/0008-5472.22417124.v1","doi":"https://doi.org/10.1158/0008-5472.22417124.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22417124.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4361257167","https://openalex.org/W2769003179","https://openalex.org/W2765145927","https://openalex.org/W3130534348","https://openalex.org/W2075890414","https://openalex.org/W4361945743","https://openalex.org/W2570352383","https://openalex.org/W3130393297","https://openalex.org/W4393086019","https://openalex.org/W3112954044"],"abstract_inverted_index":{"Supplementary":[0,15,23,39],"Figure":[1,16,24,40],"9":[2],"The":[3],"effect":[4],"of":[5,19,28,44],"treatment":[6,30],"with":[7,13,31,51],"c-myc":[8],"inhibitor":[9],"10058-F4":[10],"in":[11,37],"combination":[12,29],"niraparib":[14,54,61],"10":[17],"Screening":[18],"known":[20],"MYC-inhibiting":[21],"drugs.":[22],"11":[25],"Synergistic":[26],"assessment":[27],"dinaciclib":[32,57,63],"and":[33,62],"PARPi":[34],"on":[35],"TNBC":[36],"vitro":[38],"12":[41],"Immunofluorescent":[42],"analysis":[43],"breast":[45],"cancer":[46],"cells":[47],"treated":[48],"for":[49],"72-h":[50],"DMSO":[52],"(control),":[53],"(5":[55],"\u03bcM),":[56],"(10":[58],"nM),":[59],"or":[60],"(Combo).":[64]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2023-03-31T00:00:00"}